

---

# **HIGH CONTENT SCREENING**

**SCIENCE, TECHNIQUES  
AND APPLICATIONS**

---

**EDITED BY**

**Steven A. Haney, Ph.D.**

Department of Biological Technologies  
Wyeth Research



**WILEY-INTERSCIENCE  
A JOHN WILEY & SONS, INC., PUBLICATION**





# **HIGH CONTENT SCREENING**



---

## THE WILEY BICENTENNIAL—KNOWLEDGE FOR GENERATIONS

---

Each generation has its unique needs and aspirations. When Charles Wiley first opened his small printing shop in lower Manhattan in 1807, it was a generation of boundless potential searching for an identity. And we were there, helping to define a new American literary tradition. Over half a century later, in the midst of the Second Industrial Revolution, it was a generation focused on building the future. Once again, we were there, supplying the critical scientific, technical, and engineering knowledge that helped frame the world. Throughout the 20th Century, and into the new millennium, nations began to reach out beyond their own borders and a new international community was born. Wiley was there, expanding its operations around the world to enable a global exchange of ideas, opinions, and know-how.

For 200 years, Wiley has been an integral part of each generation's journey, enabling the flow of information and understanding necessary to meet their needs and fulfill their aspirations. Today, bold new technologies are changing the way we live and learn. Wiley will be there, providing you the must-have knowledge you need to imagine new worlds, new possibilities, and new opportunities.

Generations come and go, but you can always count on Wiley to provide you the knowledge you need, when and where you need it!

**WILLIAM J. PESCE**  
PRESIDENT AND CHIEF EXECUTIVE OFFICER

**PETER BOOTH WILEY**  
CHAIRMAN OF THE BOARD

---

---

# **HIGH CONTENT SCREENING**

**SCIENCE, TECHNIQUES  
AND APPLICATIONS**

---

**EDITED BY**

**Steven A. Haney, Ph.D.**

Department of Biological Technologies  
Wyeth Research



**WILEY-INTERSCIENCE  
A JOHN WILEY & SONS, INC., PUBLICATION**

Copyright © 2008 by John Wiley & Sons, Inc. All rights reserved

Published by John Wiley & Sons, Inc., Hoboken, New Jersey

Published simultaneously in Canada

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Sections 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400, fax 978-646-8600, or on the web at [www.copyright.com](http://www.copyright.com). Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008.

**Limit of Liability/Disclaimer of Warranty:** While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services please contact our Customer Care Department within the U.S. at 877-762-2974, outside the U. S. at 317-572-3993 or fax 317-572-4002.

Wiley also publishes its books in variety of electronic formats. Some content that appears in print, however, may not be available in electronic format.

***Library of Congress Cataloging-in-Publication Data:***

High content screening : science, techniques, and applications/[edited by] Steven A. Haney.

p. cm.

ISBN 978-0-470-03999-1 (cloth)

1. Biological systems—Research—Methodology. 2. Computational biology.
  3. Combinatorial chemistry. I. Haney, Steven A.  
[DNLM: 1. Systems Biology—methods. 2. Combinatorial Chemistry Techniques.
  3. Computational Biology—methods. 4. Drug Design.
  5. Drug Evaluation, Preclinical—methods. 6. Image Processing, Computer-Assisted—methods.
- QU 26.5 H6385 2008]  
QH324.H524 2008  
615'.19—dc22

2007027361

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

*For Carolyn, Benjamin and Allison*



## CONTENTS

---

<b>Preface</b>	<b>xix</b>
<b>Contributors</b>	<b>xxi</b>
<b>SECTION I ESSENTIALS OF HIGH CONTENT SCREENING</b>	<b>1</b>
<b>1. Approaching High Content Screening and Analysis: Practical Advice for Users</b>	<b>3</b>
<i>Scott Keefer and Joseph Zock</i>	
1.1 Introduction	3
1.2 What is HCS and Why Should I Care?	4
1.3 How does HCS Compare with Current Assay Methods?	5
1.4 The Basic Requirements to Implement HCS	8
1.4.1 Cell Banking	9
1.4.2 Plating, Cell Density, and the Assay Environment	10
1.4.3 Compound Addition and Incubation	11
1.4.4 Post-Assay Processing	11
1.4.5 HCS Imaging Hardware	12
1.4.6 HCS Analysis Software	13
1.4.7 Informatics	13
1.5 The Process	15
1.6 An Example Approach	16
1.7 Six Considerations for HCS Assays	18
1.7.1 Garbage In, Garbage Out (GIGO)	18
1.7.2 This Is Not a Plate Reader	19
1.7.3 Understand Your Biology	20
1.7.4 Subtle Changes Can Be Measured and Are Significant	20
1.7.5 HCS Workflow — Flexibility is the Key	21
1.7.6 HCS is Hard — How Do I Learn It and Become Proficient at It?	21
References	22

<b>2. Automated High Content Screening Microscopy</b>	<b>25</b>
<i>Paul A. Johnston</i>	
2.1 Introduction	25
2.2 Automated HCS Imaging Requirements	26
2.3 Components of Automated Imaging Platforms	26
2.3.1 Fluorescence Imaging and Multiplexing	26
2.3.2 Light Sources	28
2.3.3 Optical Designs: Confocal Versus Wide-Field	28
2.3.4 Objectives	29
2.3.5 Detectors	29
2.3.6 Autofocus	29
2.3.7 Environmental Controls and On-Board Liquid Handling Capabilities	30
2.4 Imaging Platform Software	31
2.5 Data Storage and Management	32
2.6 Selecting an HCS Platform	32
2.7 Comparison of a SAPK Activation HCS Assay Read on an ArrayScan <sup>®</sup> 3.1, an ArrayScan <sup>®</sup> V <sup>Ti</sup> , and an IN Cell 3000 Automated Imaging Platform	33
References	40
<b>3. A Primer on Image Informatics of High Content Screening</b>	<b>43</b>
<i>Xiaobo Zhou and Stephen T.C. Wong</i>	
3.1 Background	43
3.2 HCS Image Processing	46
3.2.1 Image Pre-Processing	46
3.2.2 Cell Detection, Segmentation, and Centerline Extraction	48
3.2.2.1 Cell Detection	48
3.2.2.2 Particle Detection	50
3.2.2.3 Cell Segmentation	52
3.2.2.4 Centerline/Neurite Extraction	57
3.2.3 Cell Tracking and Registration	60
3.2.3.1 Simple Matching Algorithm	60
3.2.3.2 Mean Shift	62
3.2.3.3 Kalman Filter	62
3.2.3.4 Mutual Information	63
3.2.3.5 Fuzzy-System-Based Tracking	64
3.2.3.6 Parallel Tracking	66
3.2.4 Feature Extraction	66
3.2.4.1 Features Extracted from Markov Chain Modeling of Time-Lapse Images	67
3.3 Validation	67
3.4 Information System Management	69



3.5	Data Modeling	70
3.5.1	Novel Phenotype Discovery Using Clustering	70
3.5.2	Gene Function Study Using Clustering	72
3.5.3	Screening Hits Selection and Gene Scoring for Effectors Discovery	74
3.5.3.1	Fuzzy Gene Score Regression Model	75
3.5.3.2	Experimental Results	76
3.5.4	Metabolic Networks Validated by Using Genomics, Proteomics, and HCS	76
3.5.5	Connecting HCS Analysis and Systems Biology	77
3.5.6	Metabolic Networks	78
3.6	Conclusions	79
3.7	Acknowledgments	79
	References	80
<b>4.</b>	<b>Developing Robust High Content Assays</b>	<b>85</b>
	<i>Arijit Chakravarty, Douglas Bowman, Jeffrey A. Ecsedy, Claudia Rabino, John Donovan, Natalie D'Amore, Ole Petter Veiby, Mark Rolfe, and Sudeshna Das</i>	
4.1	Introduction	85
4.2	Overview of a Typical Immunofluorescence-Based High Content Assay	86
4.2.1	Staining Protocol	87
4.2.2	Sources of Variability	87
4.3	Identifying Sources of Variability in a High Content Assay	88
4.3.1	Verifying the Accuracy and Precision of Liquid Handling Procedures	89
4.3.2	Deconstruction of Immunofluorescence and Cell Culture Protocols	90
4.3.3	Control Experiments	90
4.3.4	Protocol Optimization	92
4.3.5	Antibody Optimization Using a Design of Experiments Framework	94
4.3.6	Addressing Sources of Variability in Microscopy	96
4.3.7	Optimization of Image Processing Parameters in a High Content Assay	99
4.4	From Immunofluorescence to High Content: Selecting the Right Metric	101
4.5	Validation of High Content Assays	102
4.5.1	Establishing SOPs and Reagent Stocks for Cell Culture and Immunofluorescence Staining	103
4.5.2	Linking Assay Variability to Assay Performance	104
4.5.3	Design of Assay Quality Control Measures	105

4.6 Conclusion	107
4.7 Acknowledgments	108
References	108

## **SECTION II APPLICATIONS OF HCS IN BASIC SCIENCE AND EARLY DRUG DISCOVERY 111**

### **5. HCS in Cellular Oncology and Tumor Biology 113**

*Steven A. Haney, Jing Zhang, Jing Pan, and Peter LaPan*

5.1 Cancer Cell Biology and HCS	113
5.1.1 Oncology Research and the Search for Effective Anticancer Therapeutics	113
5.1.2 A General Protocol for Establishing HCS Assays Within Oncology Research	115
5.1.2.1 What is the Underlying Biology to be Evaluated in an HCS Assay?	115
5.1.2.2 What Resources Are Immediately Available for Characterizing the Target or its Activity?	116
5.1.2.3 How Do the Available Reagents Perform Quantitatively?	118
5.1.2.4 What Multiplexing is Required for the Assay?	119
5.2 The Cell Biology of Cell Death	120
5.2.1 Cell Death Stimuli and Response Pathways	120
5.2.2 Induction of Cell Death Signals	121
5.2.2.1 Activation of Cell Death Receptors	121
5.2.2.2 Mitochondrial Damage	122
5.2.2.3 Mitotic Arrest, Replication Stress, and DNA Damage	122
5.2.2.4 ER Stress	122
5.2.3 Propagation of Cell Death Signals into Specific Cell Death Responses	123
5.2.3.1 Apoptosis	126
5.2.3.2 Mitotic Catastrophe	127
5.2.3.3 Autophagy	127
5.2.3.4 Necrosis	128
5.2.3.5 Senescence	129
5.2.4 Cytological and High Content Assays for Cancer Cell Death	129
5.2.4.1 Detection of Moderate and Severe ER Stress in Cancer Cells	130
5.2.4.2 Effects of Cytotoxic Therapeutics on Apoptosis and Necrosis of Cancer Cells	130

5.3	Cell Signaling Pathways in Cancer	133
5.3.1	Signal Transduction in Cancer	133
5.3.2	A Multiparametric Assay for the PI3K/AKT Pathway as Representative of Quantitative Measures of Signal Transduction in Cancer Cells	135
5.4	HCS in Tumor Biology	137
5.4.1	The Biology of Tumor Growth	137
5.4.2	An HCS Assay to Study Tumor Biology <i>in vitro</i>	137
5.5	Conclusions	139
	References	139
<b>6.</b>	<b>Exploring the Full Power of Combining High Throughput RNAi with High Content Readouts: From Target Discovery Screens to Drug Modifier Studies</b>	<b>145</b>
	<i>Christoph Sachse, Cornelia Weiss-Haljiti, Christian Holz, Kathrin Regener, Francoise Halley, Michael Hannus, Corina Frenzel, Sindy Kluge, Mark Hewitson, Benjamin Bader, Amy Burd, Louise Perkins, Alexander Szewczak, Stefan Prechtel, Claudia Merz, Peter Rae, Dominik Mumberg, and Christophe J. Echeverri</i>	
6.1	Background: The Convergence of High Content Analysis and RNAi	145
6.2	Integrating HT-RNAi and HCA in Drug Discovery: The Potential	146
6.2.1	Technology Platform, HCA, and HT-RNAi Methodologies	146
6.2.2	Key Applications of HT-RNAi Combined with HCA in Drug Discovery	148
6.2.2.1	Target Discovery Screens	148
6.2.2.2	Target Validation Studies	149
6.2.2.3	Drug Mechanism of Action Screens	149
6.3	Combining RNAi and HCA in One Assay — The Reality	150
6.3.1	General Considerations	150
6.3.1.1	Choice of the Right Cell Model	150
6.3.1.2	Establishment of an RNAi Delivery Protocol	150
6.3.1.3	Assay Optimization	151
6.3.2	Applications: Combining HCA with HT-RNAi to Integrate Functional Validation Directly Within Target Discovery Studies	151
6.3.2.1	Multipass Strategies for Systematic Screens	151
6.3.2.2	Hurdles and Caveats	152
6.3.2.3	Example: A Multiparametric Oncology Assay Platform	155
6.3.3	RNAi Target Validation Studies	159
6.3.3.1	Functional Profiling	160

6.3.3.2	Transcriptional Profiling	160
6.3.3.3	Cytological Profiling	160
6.3.3.4	Pathway Profiling	160
6.3.3.5	Target Titration	160
6.3.4	RNAi Drug Modifier Screens	161
6.4	HCA-Based RNAi Studies — The Future	164
6.5	Acknowledgments	166
	References	166
<b>7.</b>	<b>Leveraging HCS in Neuroscience Drug Discovery</b>	<b>169</b>
	<i>Myles Fennell, Beal McIlvain, Wendy Stewart, and John Dunlop</i>	
7.1	High Content Screening and Drug Discovery	169
7.2	The Neuron and Neuronal Morphology	169
7.2.1	What Does Morphology Tell Us About Neuronal Function?	170
7.3	Methods for Measuring Neuronal Morphology	172
7.3.1	Traditional Methods	172
7.3.2	Available HCS Systems for Neuronal Morphology Measurements and Evolution of Technology	173
7.3.3	Methods for Imaging Neurons and Types of Morphologic Measurement	176
7.4	Small Molecule Screening for Neurite Outgrowth	178
7.5	RNAi in Neuroscience and HCA	179
7.6	Measurement of Signal Transduction in Neurons	180
7.7	High Content Screening in Complex CNS Models	181
7.8	Methods Used in Neuronal HCS	182
7.8.1	Preparation of Neuronal Culture Samples for HCS Morphology Analysis	182
7.8.2	Culture Fixing	183
7.8.3	Immunocytochemistry	183
7.8.4	Neurite Morphology Measurement and Analysis	184
	References	185
<b>8.</b>	<b>Live Brain Slice Imaging for Ultra High Content Screening: Automated Fluorescent Microscopy to Study Neurodegenerative Diseases</b>	<b>189</b>
	<i>O. Joseph Trask, Jr., C. Todd DeMarco, Denise Dunn, Thomas G. Gainer, Joshua Eudailey, Linda Kaltenbach, and Donald C. Lo</i>	
8.1	Introduction and Background	189
8.2	Live Brain Slice Model to Study Huntington's Disease	191
8.3	Imaging Platforms	191
8.4	Center of Well (COW) for Image Processing	194
8.5	Generic Protocol for the Cellomics ArrayScan VTI	197

8.6 Data and Results	197
8.7 Discussion	201
References	203
<b>9. High Content Analysis of Human Embryonic Stem Cell Growth and Differentiation</b>	<b>205</b>
<i>Paul J. Sammak, Vivek Abraham, Richik Ghosh, Jeff Haskins, Esther Jane, Patti Petrosko, Teresa M. Erb, Tia N. Kinney, Christopher Jefferys, Mukund Desai, and Rami Mangoubi</i>	
9.1 Introduction	205
9.2 Cell Culture Methods	206
9.2.1 Maintaining Pluripotency	206
9.2.2 Cardiomyocyte Differentiation	207
9.2.3 Neuronal Differentiation	207
9.3 Statistical Wavelet-Based Analysis of Images for Stem Cell Classification	207
9.3.1 Motivation for Algorithm Development	207
9.3.2 Measuring Amorphous Biological Shapes	209
9.3.3 Texture and Borders as Biological Features	210
9.3.4 Texture Analysis	210
9.4 Molecular Analysis of Pluripotency and Cell Proliferation in Undifferentiated Stem Cells	214
9.4.1 Methods	215
9.4.2 Analysis of Pluripotency and Cell Proliferation in Undifferentiated Stem Cells	215
9.5 Analysis of Cardiomyocyte Differentiation	218
9.6 Analysis of Neuronal Differentiation	219
9.6.1 Methods	219
9.6.2 Analysis of Neurectodermal Intermediates in Early Differentiated hESC	220
9.6.3 Analysis of Neuronal Processes	221
References	221
<b>SECTION III HCS IN DRUG DEVELOPMENT</b>	<b>225</b>
<b>10. HCS for HTS</b>	<b>227</b>
<i>Ann F. Hoffman and Ralph J. Garippa</i>	
10.1 Introduction	227
10.2 HCS for Orphan GPCRs and Transfluor	228
10.3 HCS for Multiparameter Cytotoxicity Screening	236
10.4 Discussion	243
10.5 Summary	246
References	246